Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study (updated)

Cerevel Therapeutics Holdings

18/04/2024 11:51

(Adds details throughout)
       April 18 (Reuters) - Cerevel Therapeutics  CERE.O  said
on Thursday its Parkinson's disease drug met the main goal of a
late-stage trial.
    The trial was testing the drug tavapadon as an add-on
therapy to levadopa, the standard of care for Parkinson's
disease.
    The results showed that patients using these two drugs had a
statistically significant increase in the time in which they had
good control over symptoms -- such as uncontrolled, involuntary
muscle movement -- than patients given levadopa and a placebo.

 (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru;
Editing by Savio D'Souza)
 ((Sriparna.Roy@thomsonreuters.com;))